Kornimate/medical-research-clean huggingface dataset:
phase ii study of campath-1h antibody to treat waldenstrom's macroglobulinemia

Conditions: Lymphoplasmacytic Lymphoma; Waldenstrom's Macroglobulinemia

Summary: the purpose of this study is to determine the safety and effects (good or bad) of campath-1h antibody in the treatment of lymphoplasmacytic lymphoma.

* patients will receive 3 test doses of campath-1h (3mg, 10mg, 30mg). if the patient tolerates these three test doses, then they will receive a total of 6 weeks of campath-1h therapy three times a week. * after the patient receives the first 6 weeks of therapy at the 30mg therapeutic dose they will be re-assessed by blood testing. if it is determined that their disease has progressed in the period of time while the patient was on campath-1h, the patient will be removed from the study. * if it is determined that the patient has achieved a complete remission after 6 weeks of campath-1h treatment a bone marrow biopsy will be performed to confirm complete remission and the patient will not receive any additional treatment but will be followed for a period of 2 years. * if the disease has remained stable or partial response has been achieved the patient will enter the second phase of therapy in which they will receive an additional 6 weeks of campath-1h therapy. the patient will then be reassessed as described above. * no additional therapy (as part of this study) will be performed after a 12 week course of campath-1h. * while the patient is on campath-1h blood test will be performed at 3-6 month intervals over a period extending for 2 years following the last treatment. bone marrow biopsies and/or aspirations will be conducted as necessary.

Eligibility criteria:
inclusion criteria: * diagnosis of lymphoplasmacytic lymphoma including patients with waldenstrom's macroglobulinemia * adequate organ function: anc \> 500/ul; plt \> 25,000/ul; serum creatinine \< 2.5; serum total bilirubin and sgot \< 2.5 times the upper normal limit. * age greater than 18 years * life expectancy of 6 months or greater * ecog performance status of 0-2 exclusion criteria: * chemotherapy, steroid therapy, or radiation therapy within 21 days of study entry. * prior campath-1h or monoclonal antibody therapy within 3 months of study entry. * pregnant women * serious co-morbid disease, uncontrolled bacterial, fungal, or viral infection.

Keywords: lymphoplasmacytic lymphoma waldenstrom's macroglobulinemia antibody campath-1h
a single-ascending and repeated dose study of ly3849891 in participants with metabolic dysfunction-associated steatotic liver disease (masld)

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Summary: the main purpose of this study is to evaluate the safety and tolerability of the study drug ly3849891 in participants with metabolic dysfunction-associated steatotic liver disease (masld) who have the patatin-like phospholipase domain-containing protein 3 (pnpla3) i148m genotype. blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of ly3849891 on masld and assessment of resolution of liver fibroinflammation. blood tests will also determine how long it takes the body to eliminate ly3849891. this is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts a and b.


Eligibility criteria:
inclusion criteria: * participants must have a body mass index (bmi) within the range greater than or equal to (≥) 25 and less than (\<) 50 kilogram per square meter (kg/m²) inclusive * participants must have liver fat content ≥10% in part a and ≥8% for part b as determined by mri-pdff * participants must be carriers of the pnpla3 i148m allele * participants with or without type 2 diabetes mellitus (t2dm) o for participants with t2dm, hemoglobin a1c (hba1c) \<8% in part a and \<9% in part b * male participants agree to use an effective method of contraception for the duration of the study and for 90 days after the last dose of study intervention * women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or those who are postmenopausal exclusion criteria: * participants must not have known or suspected alcohol abuse (\>14 units/week for women and \>21 units/week for men) or active substance abuse * participants must not have evidence of cirrhosis or other forms of liver disease * participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months * participants must not have active cancer within the last 5 years * participants must not have uncontrolled high blood pressure * participants must not have renal impairment with estimated glomerular filtration rate (egfr) \<60 milliliter per minute per 1.73 square meter (ml/min/1.73m²) * participants must not have a diagnosis of type 1 diabetes * participants must not have a contraindication to mri examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve) or other contraindications for mri

Keywords: hepatic fibrosis biomarkers magnetic resonance imaging pharmacokinetics liver fat
assessing the knowledge and the willingness to accept renal transplantation as a treatment option among ckd patients

Conditions: Assessing the Knowledge and the Willingness to Accept Renal Transplantation As a Treatment Option Among CKD Patients, a Cross-sectional Study

Summary: assessing the knowledge and the willingness to accept renal transplantation as a treatment option among ckd patients, a cross-sectional study

kidney transplantation in ckd patient

Eligibility criteria:
inclusion criteria: * age \&gt;18 years * patients diagnosed to have ckd stage iii- stage v (including patients undergoing regular haemodialysis) regardless the duration of the disease exclusion criteria: * ckd patients of stage i or ii of the disease * patients with aki * patients refusing to answer the questionnaire * patients who are unable to understand the questionnaire * patients underwent kidney transplantation
pain and hemodynamics in peripheral arterial disease: response to pulsed electromagnetic treatment

Conditions: Peripheral Arterial Disease

Summary: patients with peripheral arterial disease are recommended to perform all exercise forms including elliptical type. electromagnetic treatment addition to exercise may increase benefits of this exercise

patients (40 elderly) with peripheral arterial disease who take their medications will be divided to older patients group that receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week) and a group (n=20) that receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)

Eligibility criteria:
inclusion criteria: * older patients * peripheral arterial disease patients exclusion criteria: * cardiac elders * respiratory elders * renal elders
effects of spinal mobilization with leg movement on pain and disability in patients with lumbar radiculopathy

Conditions: Lumbar Radiculopathy

Summary: this study will be a randomized control trial in which both genders with age between 20 to 50 years who had diagnosed with lumbar radiculopathy will be recriuted in to two groups.group a will be recieving spinal mobilzation with leg movement along with tens \& hot pack.whie group b will be given only spinal mobilization with tens \& hot pack.before and after the introduction of interventions pain,disabaility,speed of gait,cadence and slr will be checked before and after the treatment

lumbar radiculopathy is a medical condition that occurs when one or more nerve roots in the spinal cord are compressed or damaged, leading to pain, weakness, numbness or tingling sensations in the affected area of the body. this condition can be caused by herniated discs, spinal stenosis, degenerative disc disease, tumors and infections.this study will be a randomized control trial.the study will be conducted in district swabi. we will recruit the data from ncs university rehabilitation centre swabi.oswestry disbaility index will be given at the start of study and nprs to check their pain and disbaility levels.smwlm will be given to experimental group.participants will be given hot pack for 15 minutes, tens for 10 minutes.the patient receives a set of three repetitions, then three sets of six repetitions, with a 30-second break in between each set of treatments. in this session, a progression was also provided as free slr overpressure. a total of 6 sessions will be given thrice a week on alternate days for 2 consecutive weeks. the treatment will be given with 5 repetitions of smwlm and 10 repetitions of spinal mobilization with three sets of transverse glide. total time duration of the treatment will be around 25-35 minutes§ pre assessment will be conducted at baseline followed by intervention for 3 days per week for 6 consecutive weeks.final assessment will be conducted at the end of 6 weeks of intervention

Eligibility criteria:
inclusion criteria: * patients diagnosed with lumbar radiculopathy with unilateral radiating leg pain. * both genders with age between 20 to 50 years. * patient willing to participate and complete their follow-ups. * pain from (0-35 degrees) in straight leg raise(dural pain). * positive neurodynamic test i.e. slr test(35-70 degrees),which indicate sciatica) * pain more 3-5 or more on nprs. exclusion criteria: * spinal stenosis. * cauda equina syndrome. * patients having somatic referred pain. * specific diseases of spine like ankylosing spondylitis, ,vertebral collapse, rheumatoid arthritis, and spondylolisthesis. * tb spine, intermittent claudication,diabetic neuropathy. * recent infection. * mental retardation. * previous spinal surgery. * pelvis fracture.
minimal psychological intervention in diabetes patients

Conditions: Diabetes Mellitus, Type 2; Depression

Summary: the purpose of this study is to determine whether the telephone-delivered minimal psychological intervention (mpi) could improve diabetes' depressive symptom and diabetes-related immediately , as well as hba1c level in the long-term.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of diabetes disease exclusion criteria: * were using anti-depression medication * with ongoing psychological/psychiatric treatment * had been diagnosed with psychosis (ex. schizophrenia or bipolar disorder) * had severe cognitive problem or hearing impairment * lost their partner within three months

Keywords: type 2 diabetes minimal psychological intervention glycemic control depressive symptoms problem area in diabetes middle-aged and older adults hba1c protein, human
a study measuring the effectiveness, safety, and tolerability of bms-986278 in participants with lung fibrosis

Conditions: Pulmonary Fibrosis

Summary: the purpose of this study is to provide an initial evaluation of the effectiveness of bms-986278 in participants with lung fibrosis, to demonstrate the safety of bms-986278, and provide information on the drug levels of bms-986278 in these participants.


Eligibility criteria:
inclusion criteria: for the idiopathic pulmonary fibrosis (ipf) cohort * diagnosis of ipf within 7 years of screening * female and males ≥ 40 years of age for the progressive fibrotic interstitial lung disease (pf-ild) cohort * evidence of progressive ild within the 24 months before screening * female and male ≥ 21 years of age. exclusion criteria: * women of childbearing potential (wocbp) * active smokers * current malignancy or previous malignancy up to 5 years prior to screening * history of allergy to bms-986278 or related compounds other protocol-defined inclusion/exclusion criteria apply

Keywords: idiopathic pulmonary fibrosis progressive fibrotic interstitial lung disease idiopathic interstitial pneumonia fibrotic interstitial pneumonia fibrotic interstitial lung disease fibrosing interstitial lung disease interstitial lung disease
mouthwash with chlorhexidine 0.12%/ethyl alcohol 7% compared to ethyl alcohol 7%

Conditions: Neutropenia

Summary: clinical triple-blind randomized controlled trial to assess the use of two different mouthwashes to reduce the oral colonization by gramnegative bacteria in patients with chemotherapy

clinical triple-blind randomized controlled trial. with two arms to the study: 1. mouth rinses with chlorhexidine-based solution at a concentration of 0.12%, using as a vehicle to 7% ethyl alcohol. 2. mouthwashes with solution based only 7% ethyl alcohol. goal. assess whether there decrease in the rate of oral colonization by gram-negative bacteria in patients with chemotherapy by using chlorhexidine mouthwash. specific objectives: 1. the rate of the oral colonization by gram-negative bacteria initiation of chemotherapy. 2. the rate of oral colonization by gram-negative bacteria after 10 days of initiation of chemotherapy. 3. identify microbiologically gram-negative bacteria colonizing the oral cavity. secondary objectives 1. the presence of severe neutropenia and fever in each study group during the first 10 days of starting treatment

Eligibility criteria:
inclusion criteria: 1. patients over 18years, no upper age limit. 2. acceptance of participation in the study. 3. signature of informed consent. 4. inpatient and remain hospitalized for at least 10 days. 5. the following haematological diagnosis: 1. acute lymphoblastic leukemia. 2. acute myelogenous leukemia. 3. relapsed non-hodgkin lymphoma. 6. receiving chemotherapy scheme as a treatment for the underlying disease exclusion criteria: 1. patients who choose not to participate in the study. 2. patients in whom no possible mouthwashes. 3. patients who willingly choose to withdraw from the study. 4. patients who develop conditions in which the administration is not possible rinses. 5. duration of hospital stay less than 10 days, regardless of cause.
gender influence on torsadogenic actions of droperidol.

Conditions: Arrhythmia, Droperidol

Summary: postoperative nausea and vomiting (ponv) is a quite common complication affecting patients undergoing general anesthesia. there are a few pharmacological agents of well known effectiveness in reducing the risk of ponv. one of them is droperidol, which is a butyrophenone derivant. it has been widely used for the prevention and treatment of ponv due to its high effectiveness and low cost. though, droperidol has a relevant side effect, that is a repolarization prolongation. this can lead to life-threatening cardiac arrhythmias: polymorphic ventricular tachycardia (torsades de pointes, tdp) that can degenerate into ventricular fibrillation and cardiac arrest. this was a reason why in 2001 the fda issued a "black box" warning on droperidol. ever since papers focused on this problem have described the influence of small doses of droperidol on tdp genesis as weak. this could be explained by the fact, that qt/qtc (corrected qt) interval prolongation, which represents prolonged cardiac repolarization on ecg, is not the sole determinant of a drug's potential to cause arrhythmia. another electrocardiographical marker of torsadogenic action is increased transmural dispersion of repolarization (tdr). tdr represents differences in the repolarization between myocardial "layers" (like epicardium, endocardium, myocardium cells). it is believed that the induction of qt/qtc lengthening must coexist with tdr increase at the same time to promote torsadogenic changes. it has been known, on the basis of research, that females have been more potent to torsadogenic actions of pharmacological agents than males. that could be related to estrogen influence on ecg parameters, which had been proven on animal model. it hasn't been investigated, whether gender is an important factor when considering droperidol's torsadogenic potential. the aim of this study is to answer a hypothesis, that women are more potent to torsadogenic actions of droperidol in comparison with men.


Eligibility criteria:
inclusion criteria: * age between 18 and 45 years old * asa (american society of anaesthesiologists) physical status 1 and 2 exclusion criteria: * lack of informed consent * asa (american society of anaesthesiologists) physical status 3 and more * admittance of repolarisation affecting drugs like: antiarrhythmics (williams group i-iv), psychotropics, macrolides, antireflux drugs * ischaemic heart disease * cardiac failure nyha (hew york heart association) 1 and more * congenital or acquired heart defects * arrhythmias in anamnesis * hormonal contraception, * postmenopausal * neoplasms

Keywords: postoperative nausea and vomiting torsadogenic action transmural dispersion of repolarisation corrected qt interval
caries prevalence, experience and risk related factors among early middle-aged patients attending cairo university

Conditions: Dental Caries; Caries,Dental

Summary: dental caries, a widespread oral health issue, results from a complex interplay of factors including behavior, hygiene, diet, and socio-demographic aspects. while preventive measures are available, it remains prevalent globally, affecting numerous teeth per individual. improved oral hygiene practices and increased awareness have led to a reduction in caries prevalence. however, rising sugar consumption exceeds dietary guidelines, contributing to the problem. despite limited epidemiological studies in egypt, addressing individual-level factors is crucial. surveillance of oral health in the early middle age group is standard, allowing decision-makers to assess the impact of caries and oral health care provision. stratifying data by age, geography, and gender aids in understanding prevalence and planning effective prevention strategies. overall, promoting awareness of dietary habits and preventive practices is vital for improving oral health outcome so, the purpose of this study is to assess the prevalence of dental caries among early middle age patients attending dental hospital in faculty of dentistry, cairo university and to analyze the related risk factors utilizing who oral health questionnaire for adults.


Eligibility criteria:
inclusion criteria: 1. patients whose age between 35 to 44 years old. 2. patient consulting in the outpatient clinic 3. provide informed consent 4. co-operative patients approving to participate in the trial. 5. males \& females 6. egyptian exclusion criteria: 1. patients under or over this age group 2. lack of compliance 3. disabilities
feasibility of elder mistreatment voices-ci screening tool

Conditions: Elder Abuse; Elder Mistreatment

Summary: the aim of this study is to assess the feasibility of the voices elder abuse intervention among older adults with cognitive impairment.

the voices elder abuse intervention was developed and refined to promote self-identification and self-disclosure to increase reporting of elder abuse and elder mistreatment at the point-of-care in the emergency department (ed) setting. a study (n= 1000) examining the use of voices in a busy ed with cognitively intact older adults was completed. the purpose of this study is to to assess the feasibility (n= 80) of the voices screening tool among older adults with cognitive impairment.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. age 60 or above 4. montreal cognitive assessment (moca) score between 14-25 5. not in police custody 6. non-full trauma track upon arrival 7. able to consent and communicate in english 8. agrees and able to use the ipad exclusion criteria: 1. subjects who live in nursing homes or other long-term care settings 2. at the discretion of the clinician, patient will be excluded if they cannot safely undergo the studies required for participation 3. subject refusal to participate 4. subjects with clear signs of elder mistreatment 5. severe hearing and vision impairment 6. presenting with acute intoxication 7. presenting with active psychotic symptoms 8. presenting with covid-19 diagnosis and/or severe covid-19 symptoms

Keywords: digital health
pre-operative aceclofenac on the anesthetic efficacy of ianb in symptomatic irreversible pulpitis

Conditions: Irreversible Pulpitis

Summary: the aim of this randomized, double-blinded, controlled study is to evaluate the effect of pre-operative oral aceclofenac on the success of the inferior alveolar nerve block with 2% mepivacaine containing 100,000 epinephrine for patients with symptomatic irreversible pulpitis.

* the aim of this randomized, double-blinded, controlled study is to evaluate the effect of pre-operative oral aceclofenac on the success of the inferior alveolar nerve block with 2% mepivacaine containing 100,000 epinephrine for patients with symptomatic irreversible pulpitis. * patients will be clinically and radiographically examined and their eligibility will be assessed and preoperative pain will be measured using heft-parker vas. eligible patients will be treated in one visit. * patients will be randomly assigned to one of 2 groups: experimental group (taking a 100 mg of aceclofenac) and the control group (taking a placebo tablet). each tablet will be taken one hour before starting treatment. after 15 minutes of the initial inferior alveolar nerve block (ianb), the teeth will be examined using a cold pulp sensitivity test; in case of no or mild pain, the treatment will be initiated otherwise, additional ianb will be administered. * during root canal treatment, no to mild pain response will be considered success. in case of failure, supplemental anesthesia will be administrated.

Eligibility criteria:
inclusion criteria: * patients in good health (american society of anesthesiologists class i or class ii). * patients having symptomatic irreversible pulpitis in one of their mandibular molars * age is 18 years or older. * patients who can understand heft- parker visual analogue scales. * patients able to sign informed consent. exclusion criteria: * patients allergic to aceclofenac or mepivacaine. * pregnant or nursing women. * patients having active pain in more than one molar in the same quadrant. * administration of analgesics within 12 h before the administration of the study drug.

Keywords: anesthetic efficacy, irriversible pulpitis, aceclofenac